

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

2/26/2020; Page 1

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Amitriptyline Hydrochloride, USP	10.000	g				
Ethoxy Diglycol	5.0	mL				
Medisca PLO Gel Mediflo TM 30 (Pre-Mixed)	q.s. to 100.0	mL				





TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

2/26/2020; Page 2

Suggested Formula Amitriptyline Hydrochloride 10% Transdermal PLO Gel (Emulsion, 100 mL) FIN F 008 219

ECIAL PREPARATORY CONSI	DERATIONS	
Ingredient-Specific Information		
Light Sensitive (protect from li	ght whenever possible):	Amitriptyline Hydrochloride
Hygroscopic (protect from moi	sture whenever possible):	Ethoxy Diglycol
<u>Suggested Preparatory Guidelines</u>		
Non-Sterile Preparat	ion	©
<u>Processing Error /</u> <u>Testing Considerations</u> :		considerations during preparation, it is suggested to f the required quantities of ingredients.
Special Instruction:	may be classified as hazardous, p Antineoplastic and Other Hazardo Chapter <800> Hazardous Dru	more Active Pharmaceutical Ingredients (APIs) that clease refer & verify the current NIOSH list of ous Drugs in Healthcare Settings, 2016. General gs – Handling in Healthcare Settings was formally a First Supplement to USP 39-NF 34 and has a date of December 31st, 2019.
	environmental conditions, follow	ithin the appropriate facilities under adequate ing the necessary guidelines and procedures as stated hen handling hazardous drugs. Only trained and this formula.
	limited to, lab coat, protective sle	equipment (hazardous if applicable), such as but not seves, gloves both inner and outer if applicable, eard cover, eyewear, appropriate face mask, respirator cable must be worn at all times.
		procedures for hazardous drug handling including but port, storage, preparation, dispensing, administration,
		ity, please refer to all relevant guidance documents dode of Federal Regulations (CFR), Guidance for Policy Guides (CPGs).
		f very small quantities of ingredients. All calculations be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

2/26/2020; Page 3

Suggested Formula	Amitriptyline Hydrochloride 10% Transdermal PLO Gel (Emulsion, 100 mL)	FIN	F 008 219
----------------------	------------------------------------------------------------------------	-----	-----------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Amitriptyline Hydrochloride, USP §	10.000	g			
Ethoxy Diglycol	5.0	mL			
Medisca PLO Gel Mediflo™ 30 (Pre-Mixed)	q.s. to 100.0	mL	®		

- § Weigh / measure just prior to use.
- * Takes into account increased batch size conversions and density conversions, if required.

	Preparatory Instruction
1.	Powder-liquid preparation:
	A. Triturate the Amitriptyline Hydrochloride to form a fine, homogeneous powder.
	B. Levigate the fine homogeneous powder (Step 1A) with the Ethoxy Diglycol.
	End result: Homogeneous paste-like dispersion.
2.	Filling to volume:
	A. Geometrically add PLO Gel Mediflo TM 30 (Pre-Mixed) to the homogeneous paste-like dispersion (Step 1B) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).
	Specifications: Continuously mix, using high-shear mixing techniques.
	End result: Homogeneous gel-like dispersion.
3.	Product transfer:
	Transfer the final product into the specified dispensing container (see "Packaging requirements").



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

2/26/2020; Page 4

Formula Affilitriptyffine Hydrochioride 10% Transdermai PLO Get (Emulsion, 100 mL)	Suggested Formula Amit	itriptyline Hydrochloride 10% Transdermal PLO Gel (Emulsion, 100 mL)	FIN	F 008 219
------------------------------------------------------------------------------------	---------------------------	----------------------------------------------------------------------	-----	-----------

SUGGESTED PRESENTATION 90 days at 25°C or 4°C, based - Tightly closed, light-resistant ointment tube/jar. Packaging on available stability studies - To be administered with a metered-dose Requirements through Medisca* measuring device. *Suggested BUD is based on the exact execution of the indicated ingredient list, quantities and procedures listed within this formulation. **Estimated** Note: This data is provided for informational purposes only, representing the results of a study of the Beyond-Use Date product stability with various active pharmaceutical ingredients. It does not serve, and may not be construed, as a representation or guarantee of product performance. In all cases the practitioner is advised to consult recognized pharmaceutical compendia and other recognized sources for product formulation and other product characteristics, including stability. MEDISCA Network Inc. makes no warranties or representations with regard to the functioning or appropriateness of this product in any compounded formulation, which use is solely at the discretion and liability of the practitioner. Use as directed. Do not exceed prescribed Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants. dose. Keep out of reach of children. 7 Cap tightly after use. Consult your health care practitioner if any Auxiliary other prescription or over-the-counter For external use only. Labels medications are currently being used or are prescribed for future use. Keep at room temperature or, Keep May impair mental and/or physical ability. Use 4 refrigerated. Do not freeze. care when operating a car or machinery. Keep in a dry place. 10 Protect from light. Pharmacist Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. Instructions Contact your pharmacist in the event of adverse reactions. Patient Instructions **IMPORTANT:** The quantity of API administered is directly dependent on the quantity of product applied.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

2/26/2020; Page 5

Suggested Formula	Amitriptyline Hydrochloride 10% Transdermal PLO Gel (Emulsion, 100 mL)	FIN	F 008 219
----------------------	------------------------------------------------------------------------	-----	-----------

REFERENCES

1.	Ointments, Creams, and Pastes. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition</i> . American Pharmacists Association; 2016: 317.
2.	Amitriptyline Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 376.
3.	Amitriptyline (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #483.
4.	Amitriptyline Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 5 th Edition. American Pharmaceutical Association; 2012: 33.
5.	Amitriptyline Hydrochloride (Monograph). <i>United States Pharmacopeia XLI / National Formulary 36</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2019: 247.
6.	Amitriptyline. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional</i> , 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 308.
7.	USP <795>. <i>United States Pharmacopeia XLI / National Formulary 36</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2018: 6546.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2019-2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.